August 13, 2019 | Joanne Morrison
Department of Anesthesiology
(410) 328-6120 (phone)
(410) 328-5531 (fax)
Director of Marketing and Public Relations
University of Maryland School of Medicine
Office: (410) 706-2884
Mobile: (202) 841-3369
Tuesday, December 10, 2019
UMSOM Researchers to Test Vaccine Designed to Protect Against Serious Illness from Contaminated Food and Water
Each year, millions of people contract serious diarrheal illnesses typically from contaminated food and water. Among the biggest causes of diarrheal diseases are the bacteria Shigella and enterotoxigenic Escherichia coli (ETEC), and researchers at the University of Maryland School of Medicine are testing a vaccine designed to offer protection against these serious pathogens.
Friday, September 20, 2019
UM School of Medicine's Center for Vaccine Development and Global Health Receives NIH Contract of up to More than $200 Million for Influenza Research
Kathleen Neuzil, MD, MPH, Professor of Medicine and Pediatrics and Director of the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine (UMSOM) and Dean E. Albert Reece, MD, PhD, MBA, announced that CVD has been awarded a contract from the National Institute of Allergy and Infectious Diseases (NIAID), with total funding up to more than $200 million over seven years if all contract options are exercised.
Monday, August 19, 2019
Each year there are more than 200 million cases of malaria worldwide, a mosquito-borne disease caused by a parasite that brings on fever and body aches and, in some cases, more serious conditions such as coma and death. While the vast majority of these cases occur in sub-Saharan Africa and South Asia, the U.S. each year sees more than 1,500 cases, and currently there is limited access to an intravenously-administered (IV) drug needed for the more serious cases, according to a top malaria researcher at the University of Maryland School Medicine (UMSOM).
Monday, December 03, 2018
UMSOM and Groupe De Recherche Action En Sante Begin Second Typhoid Conjugate Vaccine Study in Africa
A new study has been launched in Burkina Faso for Bharat Biotech’s typhoid conjugate vaccine (TCV). It is the second clinical study underway in Africa for the vaccine and the first in West Africa. The vaccine study is a joint effort by the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine, (UMSOM) and Groupe de Recherche Action en Santé (GRAS) in Burkina Faso.
Friday, November 02, 2018
Kathleen Neuzil, MD, MPH, Professor of Medicine and Pediatrics and Director of the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine (UMSOM), has been named to the World Health Organization’s (WHO) Strategic Advisory Group of Experts (SAGE) on Immunization.
Wednesday, June 06, 2018
In regions where malaria illness is widespread, it is common to find many individuals who are infected with malaria parasites (Plasmodium falciparum), but without symptoms. New research conducted by the University of Maryland School of Medicine (UMSOM) shows that treating these silent malaria cases could help stop the spread of malaria to others.
Tuesday, May 15, 2018
Two malaria experts in the Center for Vaccine Development and Global Health at the University of Maryland School of Medicine wrote a commentary published in the June Issue of The Lancet Global Health discussing the prevalence of malaria in school-age children in sub-Saharan Africa. Miriam Laufer, MD, Associate Professor of Pediatrics and Associate Director for Malaria Research CVD, and Lauren Cohee, MD, Instructor, Pediatrics, noted that often malaria infection is more common in school-age children than younger children and adults.
Wednesday, July 06, 2016
Malaria is one of the world’s deadliest diseases: it infects hundreds of millions of people every year, and kills about half a million, most of them under five years of age.